PER (ASX) Please explain.

PER

Click for more information

10.0%

11.0¢ percheron therapeutics limited

First 9 Last

Share
Profile

Follow
kpkg

4,149 Posts.

12/07/17

05:53

Post #: 25807002
Share

Originally posted by imperatore ↑

Probably the best person to explain the following would be our friend ITSA with his
unconditional confidence in M.D.
IIL, after a disastrous announcement, drop something 95% but still the shares are
approx 80% ( today another 40% gain) more than ANP and in addition are raising daily from bottom.
On the contrary ANP regardless lately had 2-3 fairly positive announcement is not moving
from bottom. In my view this "unusual " trend is caused by some inexperience (past & present)
from management side as it seems market has lost trust in it and whatever
they say it become somehow irrelevant.

Expand

Originally posted by imperatore ↑

After 16 years of failing to get one drug permanently licensed out and registered it's hardly any wonder.
Was it 2014 or 2015 they said it would take 12 months to relicense out 1103 and they were exchanging emails on 1102 with potential interested parties.
That all amounted to nix and their word means nothing imo. Just the same as the touted revenues from the Early access program that disappeared with great mystery.
And people blame the negative posts for holding the stock back . Wow that's rich.
...this company has burnt so many investors in the past by not delivering it's hardly any wonder that there is no market confidence.
Meanwhile they plan on flogging off 20% of the company at all time historical lows ...for an amount that barely covers the cost of Diamond for another 2 years.
And this is meant to be a positive Ann ??I mean seriously you guys ...are you all that blind??
...as for the international board comment well they haven't attracted much since their appointment (coming up to 2 years?)but we did see a spectacular slide in the sp.
Really the amazing thing is that this all centres around some first generation antisense compounds that are becoming increasingly obsolete imo
The new generation of antisense drugs are more potent and supposedly less toxic so it's hardly any wonder they have not been able to find anyone on this planet to take them up.
Seriously it's been 7 years ? Since Teva handed back 1102 for something to do with a failed monkey study and now everyone gets excited that they dug up some old data. If any of the data was that good then it sure as hell wouldn't take the better part of a decade to license out 1102 again....but here we are with patent life running out and new drugs superseding.
That is the reality and there are all the above reasons and more for why and where this capital sucking company is today.

Expand

ANP Price at posting: 3.7¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

VNL

Vinyl expands into UK and European markets with acquisition of Serenade platform

ALY

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 44 more messages in this thread...

First 9 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 11.0¢		Change 0.010(10.0%)		Mkt cap ! $90.15M

Open	High	Low	Value	Volume
11.0¢	11.0¢	11.0¢	$35.07K	318.8K

Buyers (Bids)

No.	Vol.	Price($)
5	331945	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	430148	4

View Market Depth

No.	Vol.	Price($)
3	141643	0.110
5	396276	0.105
10	588005	0.100
3	113179	0.099
1	13000	0.098

Price($)	Vol.	No.
0.100	13669	1
0.105	97936	4
0.110	290000	4
0.115	401850	4
0.120	275642	8

Last trade - 10.07am 30/09/2024 (20 minute delay)

PER (ASX) Chart

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Vinyl expands into UK and European markets with acquisition of Serenade platform

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Vinyl expands into UK and European markets with acquisition of Serenade platform

Alchemy signs farm-in agreement with Japanese government for development of WA's Karonie

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News